2014-11-26 23:03:10 UTC

CGH Podcast November 2014: Mesalamine Dosage and Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis

A study in the November issue of CGH investigated whether increasing doses of mesalamine reduces concentrations of fecal calprotectin in patients with quiescent ulcerative colitis. Dr. Kuemmerle speaks to co-author Dr. James Lewis of the Perelman School of Medicine at the University of Pennsylvania; Plus, summaries of top stories from this month's issue of GI and Hepatology News.

 

 

Osterman MT, Aberra FN, Cross R. Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology & Hepatology 2014; November 12(11): 1887–1893.e3
Abstract

 

 

 

Duration: 15.20m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

 

 

More on Ulcerative Colitis

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

AGA Campaign to Raise Awareness of IBD in Patients of Childbearing Years

May 18, 2017

UCB provides support, research and education of health-care professionals and patients surrounding the issue.

Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis

April 28, 2017

We found that among patients with UC-LGD under surveillance, the annual incidence of progression to CRC was 0.8%; differences in rates of LGD diagnosis varied with pathologists’ level of expertise.